A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.
Status:
Active, not recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to understand how ipilimumab is being used, its safety profile, and
the manner in which Adverse Reactions are managed in routine clinical practice. Another goal
is to identify predictive biomarkers. The study is an observational study and not intended to
test any hypothesis, but can be hypothesis generating.